NLS PHARMACEUTICS AG

NLS PHARMACEUTICS AG

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its two lead product candidates, include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was founded in 2015 and is based in Stans, Switzerland.

NLS Pharmaceutics AG_logo

Industry:
Organization

Address:
Alter Postplatz 2, Stans, Switzerland Zipcode 6370

Country:
Switzerland

Phone:
41 41 618 80 00

Market Cap:
37.73M
Total Assets:
696.43k
Total Cash:
220.27k


Key Executives
Name Title Pay Year Born
Mr. Alexander Zwyer M.B.A. Pres, CEO & Director N/A 1969(51 years old)
Mr. Subhasis Roy M.B.A. Interim Chief Financial Officer N/A N/A
Dr. Silvia Panigone Chief Operating Officer N/A 1972(48 years old)
Dr. Christian C. Wenger L.L.M., Dr. iur., Ph.D., LL.M. Gen. Counsel N/A 1964(56 years old)
Ms. Sharon Keys Head of Regulatory Affairs N/A N/A



Financial & Stock
Exchange NasdaqGS. Currency in USD. Market state POSTPOST
According to NLS Pharmaceutics AG's financial reports the company's revenue in 2019 were 0 an decrease(NAN%) over the years 2018 revenue that were of 0. In 2019 the company's total earnings were -5.45M while total earnings in 2018 were -5.15M(0%).
Company's stock symbol is NLSP. Lastest price : 3.2000. Total volume :401.59k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.nlspharma.com

  • Host name: sl166.web.hostpoint.ch
  • IP address: 217.26.53.155
  • Location: Switzerland
  • Latitude: 47.1449
  • Longitude: 8.1551
  • Timezone: Europe/Zurich

Loading ...
Loading ...


More informations about "NLS Pharmaceutics AG" on Search Engine

Nlspharma.com NLS Pharmaceutics | We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.

Nlspharma.com » Pipeline | We design affordable, safe and effective drugs to safeguard and empower …

Nlspharma.com » Mazindol | We design affordable, safe and effective drugs to safeguard and empower …

Nlspharma.com » Press Releases | We design affordable, safe and effective drugs to safeguard and …

Nlspharma.com » R&D Strategy | We design affordable, safe and effective drugs to safeguard and …

Nlspharma.com » Leadership Team | We design affordable, safe and effective drugs to safeguard and …

Nlspharma.com NLS Pharmaceutics is very interested in hearing from you. Please find general …

Nlspharma.com » Press Room | We design affordable, safe and effective drugs to safeguard and empower …

Nlspharma.com » Academic Collaborations | We design affordable, safe and effective drugs to …

Nlspharma.com » Financial Information | We design affordable, safe and effective drugs to safeguard and …

Nlspharma.com » Corporate Code of Ethics | We design affordable, safe and effective drugs to …

NLSP: NLS Pharmaceutics AG - Stock Price, Quote and News

Cnbc.com NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on …

NLS Pharmaceutics AG (NLSP) - Yahoo

Finance.yahoo.com NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for …

NLS Pharmaceutics AG Stock , NLSP - Markets Insider

Markets.businessinsider.com NLS Pharmaceutics AG Stock , NLSP. 3.83-0.04 -0.97% After-market 05:05:18 PM NAS. Add to watchlist Start Trading >> Plus500. 76.4% of retail CFD accounts lose money. 3.87-0 ...

NLS Pharmaceutics AG (NLSP) - Yahoo

Finance.yahoo.com NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system …

NLSP - Stock quote for NLS Pharmaceutics AG - MSN Money

Msn.com NLS Pharmaceutics AG (NLSP) Yahoo Finance 3/11/2021 Mid-day market update: Evoke Pharma falls following Q4 earnings; NLS Pharmaceutics shares climb

NLSP.OQ - NLS Pharmaceutics AG Profile | Reuters

Reuters.com NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on …

Should You Buy NLSP Stock?

Stockinvest.us The NLS Pharmaceutics AG stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.

A Lesson to Learn: NLS Pharmaceutics AG (NLSP) – News Heater

Newsheater.com Mar 12, 2021 · NLS Pharmaceutics AG (NASDAQ:NLSP) went up by 99.64% from its latest closing price compared to the recent 1-year high of $4.00. The company’s stock price has collected 20.00% of gains in the last five trading sessions.

A Lesson to Learn: NLS Pharmaceutics AG (NLSP) – News Heater

Newsheater.com Mar 16, 2021 · Companies NLS Pharmaceutics AG (NASDAQ:NLSP) went down by -16.58% from its latest closing price compared to the recent 1-year high of $7.35. The company’s stock price has collected 96.77% of gains in the last five trading sessions.

NLS Pharmaceutics AG (NASDAQ:NLSP): Here’s What’s Really

Stocksregister.com Apr 05, 2021 · NLS Pharmaceutics AG has a P/E ratio of 0, compared to Zoetis Inc Cl A’s 46.13 and Takeda Pharmaceutical Co. Ltd’s 35.67. Also in last trading session, the S&P 500 Index has surged 1.18%, while the Dow Jones Industrial also saw a positive session, up +0.52% on the day.

NLS Pharmaceutics AG (NLSP : NASDAQ) Stock Price & News

Google.com Get the latest NLS Pharmaceutics AG (NLSP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.

NLSP NLS Pharmaceutics AG Stock Quote - FINVIZ.com

Finviz.com NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders.

NLS Pharmaceutics AG (NLSP) Stock Price Today, Quote

Seekingalpha.com Oct 20, 2020 · NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders.

NLS Pharmaceutics AG Interactive Stock Chart (NLSP)

Investing.com Get instant access to a free live streaming chart of the NLS Pharmaceutics AG Stock. The chart is intuitive yet powerful, offering users multiple chart types including candlesticks, area, lines ...

Is NLS Pharmaceutics AG (NASDAQ:NLSP) Expensive At $3.77

Marketingsentinel.com Mar 27, 2021 · NLS Pharmaceutics AG (NASDAQ:NLSP) trade information. Wall Street analysts have assigned a consensus price target of $10 to the stock, which implies a rise of 165.25% to its current value. Analysts have been projecting $8 as a low price target for the stock while placing it at a …

NLS Pharmaceutics AG | LinkedIn

Linkedin.com NLS Pharmaceutics AG | 111 followers on LinkedIn. Connecting Brains | MISSION & VALUES To serve our patients we design affordable, safe and effective therapeutics to safeguard and empower the ...

NLS Pharmaceutics Ltd NLSP - Quotes, Financials, News

Money.usnews.com NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders. These disorders include narcolepsy, idiopathic...

What Do Analysts Say About NLS Pharmaceutics AG (NLSP)

Baxterreport.com Apr 05, 2021 · What Do Analysts Say About NLS Pharmaceutics AG (NLSP)? By. Noah Smith - April 5, 2021. Facebook. Twitter. Pinterest. WhatsApp. How have the shares performed? The 2021 Backdoor Crypto Portfolio (free)

Stock Summary - TD Ameritrade

Research.tdameritrade.com NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Time to Buy Beat-Down NLS Pharmaceutics AG (NLSP) Stock

Investchronicle.com Mar 16, 2021 · Presently, NLS Pharmaceutics AG shares are logging -33.61% during the 52-week period from high price, and 136.89% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the …

NLS Pharmaceutics AG (NASDAQ:NLSP) In 2021: Will It Be

Marketingsentinel.com Mar 16, 2021 · NLS Pharmaceutics AG (NLSP) projections and forecasts Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of 0%. NLS Pharmaceutics AG earnings are expected to decrease by -5.8% in 2021, but the outlook is negative 0% per year for the next five years.

NLSP NLS Pharmaceutics AG — Stock Price and Discussion

Stocktwits.com Apr 13, 2021 · NLS Pharmaceutics AG NASDAQ Updated Apr 13, 2021 7:16 PM. NLSP 3.26 0.46 (12.36%). 3,661

Cantel Medical Corp. (CMD), NLS Pharmaceutics AG (NLSP)

Bovnews.com Mar 20, 2021 · NLS Pharmaceutics AG (NASDAQ:NLSP)’s Williams Percent Range or Williams %R at the time of writing to be seated at 65.44% for 9-Day. It is also calculated for different time spans. Currently for this organization, Williams %R is stood at 60.49% for 14-Day, 60.49% for 20-Day.

Company Fundamentals

Research.tdameritrade.com Apr 12, 2021 · Company profile. NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment.

NLS Pharmaceutics : in Licensing Deal for Sanorex With

Marketscreener.com NLS Pharmaceutics Ltd. said it has entered into a license agreement with Novartis Pharma AG to obtain, on an exclusive basis in the U.S., all of the available data referred to and included in the original NDA for Sanorex mazindol submitted to the Food and Drug Administration in February 1972.

NLS Pharmaceutics : Shares Double on Licensing Agreement

Marketscreener.com By Chris Wack . NLS Pharmaceutics Ltd. shares doubled to $6.35 after the company said it entered into a license agreement with Novartis Pharma AG to obtain, on an exclusive basis in the U.S., all of the available data referred to and included in the original NDA for Sanorex mazindol submitted to the Food and Drug Administration in 1972.

Analysts believe NLS Pharmaceutics AG (NASDAQ:NLSP)’s

Stocksregister.com Mar 15, 2021 · NLS Pharmaceutics AG (NASDAQ:NLSP)’s beta value is currently sitting at 0, while the Average True Range indicator is currently displaying 0.72. With analysts defining $8-$12 as the low and high price targets, we arrive at a consensus price target of $10 for the trailing 12-month period.

NLSP Stock Forecast, Price & News (NLS Pharmaceutics)

Marketbeat.com NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such ...

NLSP Stock Price & Charts | NLS Pharmaceutics

Ycharts.com --Analyst Actions: Brookline Capital Initiates Coverage on NLS Pharmaceutics AG With Buy Rating, $12 Price Target. 03/12 13:10. MT Newswires. Sector Update: Health Care Stocks Narrowly Lower in Recent Trade. 03/12 13:07. SA Breaking News. MVIS, RIDE, XXII and MRKR among midday movers.

About NLS Pharmaceutics AG (NLSP) - Investing.com

Investing.com NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on …

NLS Pharmaceutics AG [NLSP] Stock trading around $5.85 per

Dbtnews.com Mar 15, 2021 · NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into a License Agreement (the “Agreement”) with Novartis Pharma AG, whereby the …

Two long Player in Depressed Market: Hudson Technologies

Bovnews.com Feb 16, 2021 · NLS Pharmaceutics AG (NLSP) shares on Friday’s trading session, dropped -2.27 percent to see the stock exchange hands at $3.45 per unit. Lets a quick look at company’s past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month ...

IPO Update: NLS Pharmaceutics Readies $20 Million IPO Plan

Seekingalpha.com Oct 20, 2020 · NLS Pharmaceutics Ltd. intends to raise $20 million from the sale of units comprising its common stock and warrants in an IPO, according to an amended registration statement.

Here is why NLS Pharmaceutics AG (NLSP) stock rallied on

Parktelegraph.com Mar 15, 2021 · NLS Pharmaceutics AG (NLSP) stock soared 107.45% on Friday, March 12, 2021, and it just lost 2.74% in the pre-market session of today March 15, 2021, as of this writing. Let see what was the reason behind such a high peak. NLSP License agreement with Novartis The NLSP stock doubled in …

NLS Pharmaceutics AG (NLSP) Is Higher By 6.35% Before the

Investorsobserver.com Mar 16, 2021 · NLS Pharmaceutics AG (NLS Pharmaceutics AG has fallen Tuesday morning, with the stock falling -6.35% in pre-market trading to 4.57.NLSP's short-term technical score of 41 indicates that the stock has traded less bullishly over the last month than 59% of stocks on the market.

NLS Pharmaceutics AG (NLSP) | AAII Stock Evaluator

Aaii.com NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

NLS Pharmaceutics AG (NLSP) distance from 20-day Simple

Investchronicle.com Feb 19, 2021 · NLS Pharmaceutics AG (NLSP) in the eye of market guru’s. During the last month, 0 analysts gave the NLS Pharmaceutics AG a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

Are we looking at the next big move in NLS Pharmaceutics

Newsrts.com Apr 05, 2021 · NLS Pharmaceutics AG (NASDAQ: NLSP) is 42.56% higher on its value in year-to-date trading and has touched a low of $2.06 and a high of $7.35 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in …

SEC.gov | HOME

Sec.gov NLS Pharmaceutics AG. Alter Postplatz 2. CH-6370 Stans "Borrower" and . Magnetic Rock Investment AG. c/o Ronald Hafner. Weinbergstrasse 72. CH-8703 Erlenbach ZH "Lender" (Borrower and Lender each a ʺPartyʺ. collectively the ʺPartiesʺ)

NLS Pharmaceutics AG - startup.ch

Startup.ch NLS Pharmaceutics AG: NLS Pharmaceutics Ltd. is a privately owned, Swiss-based biotech firm focusing on the development of new treatments for sleep disorders, such as narcolepsy, ADHD, cognitive impairment and other neurological disorders that remain largely under-diagnosed and …

Is it Time to Dump NLS Pharmaceutics AG (NLSP) Stock After

Investorsobserver.com Mar 29, 2021 · More About NLS Pharmaceutics AG. NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. The company focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible ...

NLS Pharmaceutics Obtains License to Full Regulatory Data

Apnews.com Mar 12, 2021 · STANS, Switzerland, March 12, 2021 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that it has entered into a License Agreement (the …

SEC.gov | HOME

Sec.gov Exhibit 10.6 . NLS Pharmaceutics AG. Alter Postplatz 2. CH-6370 Stans ___ September 2019 . Addendum Promissory Note (“Addendum”) [Name], [Address] (the “Lender”), granted to NLS Pharmaceutics AG (formerly NLS-1 Pharma AG), a Swiss stock corporation with its registered office at Alter Postplatz 2, 6370 Stans, Switzerland, and company no. CHE-447.067.367 (the “Borrower”), …

NLS Pharmaceutics AG Buy - Markets Insider

Markets.businessinsider.com Mar 03, 2021 · NLS Pharmaceutics AG Buy. The analysts of Maxim Group have rated NLS Pharmaceutics with a Buy rating. The price target was set to $ 8.00. At a current price of $ 3.87 there is upside potential of ...

60 Biggest Movers From Friday | Benzinga

Benzinga.com Mar 15, 2021 · NLS Pharmaceutics AG (NASDAQ: NLSP) shares climbed 106.7% to close at $5.85 on Friday in reaction to a License Agreement with Novartis Pharma AG, a unit of Novartis, wherein NLS …